{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-072689","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.017979+00:00","generated_at":"2026-06-04T11:45:21.549386+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Homology Medicines approves 1-for-18 reverse stock split effective March 25 in connection with Q32 merger","bullets":["Board approved reverse stock split at 1-for-18 ratio; every 18 shares combine into one.","Reverse split effective at market open on March 25, 2024; Certificate of Amendment filed March 22.","No fractional shares issued; stockholders receive cash in lieu based on March 22 closing price.","Reverse split is a condition to closing of the merger with Q32 Bio Inc.","Post-split common stock trades under new CUSIP 746964105."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-072689","json":"https://secwatch.observer/filing/0001193125-24-072689.json","markdown":"https://secwatch.observer/filing/0001193125-24-072689.md","text":"https://secwatch.observer/filing/0001193125-24-072689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312524072689/0001193125-24-072689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312524072689/d808597d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:45:21.549386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}